Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease

Brain. 2012 Jun;135(Pt 6):1724-35. doi: 10.1093/brain/aws095. Epub 2012 May 7.

Abstract

Gaucher's disease, the most common lysosomal storage disorder, is caused by the defective activity of glucocerebrosidase, the lysosomal hydrolase that degrades glucosylceramide. The neuronopathic forms of Gaucher's disease are characterized by severe neuronal loss, astrocytosis and microglial proliferation, but the cellular and molecular pathways causing these changes are not known. In the current study, we delineate the role of neuroinflammation in the pathogenesis of neuronopathic Gaucher's disease and show significant changes in levels of inflammatory mediators in the brain of a neuronopathic Gaucher's disease mouse model. Levels of messenger RNA expression of interleukin -1β, tumour necrosis factor-α, tumour necrosis factor-α receptor, macrophage colony-stimulating factor and transforming growth factor-β were elevated by up to ∼30-fold, with the time-course of the increase correlating with the progression of disease severity. The most significant elevation was detected for the chemokines CCL2, CCL3 and CCL5. Blood-brain barrier disruption was also evident in mice with neuronopathic Gaucher's disease. Finally, extensive elevation of nitrotyrosine, a hallmark of peroxynitrite (ONOO(-)) formation, was observed, consistent with oxidative damage caused by macrophage/microglia activation. Together, our results suggest a cytotoxic role for activated microglia in neuronopathic Gaucher's disease. We suggest that once a critical threshold of glucosylceramide storage is reached in neurons, a signalling cascade is triggered that activates microglia, which in turn releases inflammatory cytokines that amplify the inflammatory response, contributing to neuronal death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antigens, CD / metabolism
  • Antigens, Differentiation, Myelomonocytic / metabolism
  • Blood-Brain Barrier / physiopathology
  • Calcium-Binding Proteins / metabolism
  • Cell Death / drug effects
  • Cytokines / genetics
  • Cytokines / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Encephalitis / diagnosis
  • Encephalitis / drug therapy
  • Encephalitis / etiology*
  • Encephalitis / pathology
  • Endothelial Cells / pathology
  • Enzyme-Linked Immunosorbent Assay / methods
  • Gaucher Disease / complications*
  • Gaucher Disease / drug therapy
  • Gaucher Disease / genetics
  • Gene Expression Regulation, Developmental / genetics
  • Glucosylceramidase / deficiency
  • Ibuprofen / therapeutic use
  • Immunoglobulin G / metabolism
  • Intercellular Adhesion Molecule-1 / metabolism
  • Intermediate Filament Proteins / genetics
  • Magnetic Resonance Imaging
  • Mice
  • Mice, Transgenic
  • Microfilament Proteins / metabolism
  • Microglia / pathology
  • Nerve Tissue Proteins / genetics
  • Nestin
  • Neurons / drug effects
  • Neurons / pathology*
  • TATA Box
  • Tyrosine / analogs & derivatives
  • Tyrosine / metabolism
  • Vascular Cell Adhesion Molecule-1 / metabolism

Substances

  • Aif1 protein, mouse
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD68 antigen, human
  • Calcium-Binding Proteins
  • Cytokines
  • Immunoglobulin G
  • Intermediate Filament Proteins
  • Microfilament Proteins
  • NES protein, human
  • Nerve Tissue Proteins
  • Nes protein, mouse
  • Nestin
  • Vascular Cell Adhesion Molecule-1
  • Intercellular Adhesion Molecule-1
  • 3-nitrotyrosine
  • Tyrosine
  • Glucosylceramidase
  • Ibuprofen